Login to Your Account



In The Clinic NEWS
Roche AG unit Genentech Inc. said top-line data from a phase III study of Kadcyla (ado-trastuzumab emtansine) failed to beat the standard of care, Herceptin (trastuzumab) and a taxane, in helping people with previously untreated advanced HER2-positive breast cancer live longer without their disease worsening.

DUBLIN – Top-line data indicate the optimal dose of Poxel SA's first-in-class diabetes drug imeglimin hit the primary endpoint of a phase IIb dose-finding study in 382 patients with type 2 diabetes, with an average reduction in glycosylated hemoglobin (HbA1c) levels of 0.63 percent.

HONG KONG – The R&D arm of a China-based health care group owned by the multinational conglomerate Hutchison Whampoa Ltd. (HK:13) has moved its leading oncology candidate into phase III.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: